These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
289 related articles for article (PubMed ID: 11477559)
1. Detection and quantification of CD8(+) T cells specific for HLA-A*0201-binding melanoma and viral peptides by the IFN-gamma-ELISPOT assay. Griffioen M; Borghi M; Schrier PI; Osanto S Int J Cancer; 2001 Aug; 93(4):549-55. PubMed ID: 11477559 [TBL] [Abstract][Full Text] [Related]
2. Analysis of T-cell responses in metastatic melanoma patients vaccinated with dendritic cells pulsed with tumor lysates. Griffioen M; Borghi M; Schrier PI; Osanto S; Schadendorf D Cancer Immunol Immunother; 2004 Aug; 53(8):715-22. PubMed ID: 14997347 [TBL] [Abstract][Full Text] [Related]
3. Ex vivo IFN-gamma secretion by circulating CD8 T lymphocytes: implications of a novel approach for T cell monitoring in infectious and malignant diseases. Pittet MJ; Zippelius A; Speiser DE; Assenmacher M; Guillaume P; Valmori D; Liénard D; Lejeune F; Cerottini JC; Romero P J Immunol; 2001 Jun; 166(12):7634-40. PubMed ID: 11390521 [TBL] [Abstract][Full Text] [Related]
4. Validation of a HLA-A2 tetramer flow cytometric method, IFNgamma real time RT-PCR, and IFNgamma ELISPOT for detection of immunologic response to gp100 and MelanA/MART-1 in melanoma patients. Xu Y; Theobald V; Sung C; DePalma K; Atwater L; Seiger K; Perricone MA; Richards SM J Transl Med; 2008 Oct; 6():61. PubMed ID: 18945350 [TBL] [Abstract][Full Text] [Related]
5. Detection and quantification of blood-derived CD8+ T lymphocytes secreting tumor necrosis factor alpha in response to HLA-A2.1-binding melanoma and viral peptide antigens. Herr W; Schneider J; Lohse AW; Meyer zum Büschenfelde KH; Wölfel T J Immunol Methods; 1996 May; 191(2):131-42. PubMed ID: 8666832 [TBL] [Abstract][Full Text] [Related]
6. Analysis of the T cell response to tumor and viral peptide antigens by an IFNgamma-ELISPOT assay. Scheibenbogen C; Lee KH; Stevanovic S; Witzens M; Willhauck M; Waldmann V; Naeher H; Rammensee HG; Keilholz U Int J Cancer; 1997 Jun; 71(6):932-6. PubMed ID: 9185691 [TBL] [Abstract][Full Text] [Related]
7. HLA-independent heterogeneity of CD8+ T cell responses to MAGE-3, Melan-A/MART-1, gp100, tyrosinase, MC1R, and TRP-2 in vaccine-treated melanoma patients. Reynolds SR; Celis E; Sette A; Oratz R; Shapiro RL; Johnston D; Fotino M; Bystryn JC J Immunol; 1998 Dec; 161(12):6970-6. PubMed ID: 9862732 [TBL] [Abstract][Full Text] [Related]
8. Paucity of functional T-cell memory to melanoma antigens in healthy donors and melanoma patients. Dhodapkar MV; Young JW; Chapman PB; Cox WI; Fonteneau JF; Amigorena S; Houghton AN; Steinman RM; Bhardwaj N Clin Cancer Res; 2000 Dec; 6(12):4831-8. PubMed ID: 11156242 [TBL] [Abstract][Full Text] [Related]
9. Suboptimal activation of CD8(+) T cells by melanoma-derived altered peptide ligands: role of Melan-A/MART-1 optimized analogues. Carrabba MG; Castelli C; Maeurer MJ; Squarcina P; Cova A; Pilla L; Renkvist N; Parmiani G; Rivoltini L Cancer Res; 2003 Apr; 63(7):1560-7. PubMed ID: 12670905 [TBL] [Abstract][Full Text] [Related]
10. gp100(209-2M) peptide immunization of human lymphocyte antigen-A2+ stage I-III melanoma patients induces significant increase in antigen-specific effector and long-term memory CD8+ T cells. Walker EB; Haley D; Miller W; Floyd K; Wisner KP; Sanjuan N; Maecker H; Romero P; Hu HM; Alvord WG; Smith JW; Fox BA; Urba WJ Clin Cancer Res; 2004 Jan; 10(2):668-80. PubMed ID: 14760090 [TBL] [Abstract][Full Text] [Related]
11. Simultaneous CD8+ T cell responses to multiple tumor antigen epitopes in a multipeptide melanoma vaccine. Valmori D; Dutoit V; Ayyoub M; Rimoldi D; Guillaume P; Liénard D; Lejeune F; Cerottini JC; Romero P; Speiser DE Cancer Immun; 2003 Oct; 3():15. PubMed ID: 14580186 [TBL] [Abstract][Full Text] [Related]
12. Lack of terminally differentiated tumor-specific CD8+ T cells at tumor site in spite of antitumor immunity to self-antigens in human metastatic melanoma. Mortarini R; Piris A; Maurichi A; Molla A; Bersani I; Bono A; Bartoli C; Santinami M; Lombardo C; Ravagnani F; Cascinelli N; Parmiani G; Anichini A Cancer Res; 2003 May; 63(10):2535-45. PubMed ID: 12750277 [TBL] [Abstract][Full Text] [Related]
13. Identification of HLA-A*03, A*11 and B*07-restricted melanoma-associated peptides that are immunogenic in vivo by vaccine-induced immune response (VIIR) analysis. Reynolds SR; Celis E; Sette A; Oratz R; Shapiro RL; Johnston D; Fotino M; Bystryn JC J Immunol Methods; 2000 Oct; 244(1-2):59-67. PubMed ID: 11033019 [TBL] [Abstract][Full Text] [Related]
14. In vivo activation of melanoma-specific CD8(+) T cells by endogenous tumor antigen and peptide vaccines. A comparison to virus-specific T cells. Speiser DE; Liénard D; Pittet MJ; Batard P; Rimoldi D; Guillaume P; Cerottini JC; Romero P Eur J Immunol; 2002 Mar; 32(3):731-41. PubMed ID: 11870617 [TBL] [Abstract][Full Text] [Related]
15. Novel approach to the characterization of melanoma associated-peptide-specific CTL lines from Japanese metastatic melanoma patients. Akiyama Y; Maruyama K; Tai S; Takikawa M; Ohshita C; Yamamoto A; Yamazaki N; Kiyohara Y; Yamaguchi K Int J Oncol; 2008 Sep; 33(3):433-41. PubMed ID: 18695871 [TBL] [Abstract][Full Text] [Related]
16. Melan-A/MART1 analog peptide triggers anti-myeloma T-cells through crossreactivity with HM1.24. Christensen O; Lupu A; Schmidt S; Condomines M; Belle S; Maier A; Hose D; Neuber B; Moos M; Kleist C; Terness P; Ho AD; Goldschmidt H; Klein B; Hundemer M J Immunother; 2009; 32(6):613-21. PubMed ID: 19483648 [TBL] [Abstract][Full Text] [Related]
17. Peptide-specific CTL in tumor infiltrating lymphocytes from metastatic melanomas expressing MART-1/Melan-A, gp100 and Tyrosinase genes: a study in an unselected group of HLA-A2.1-positive patients. Spagnoli GC; Schaefer C; Willimann TE; Kocher T; Amoroso A; Juretic A; Zuber M; Luscher U; Harder F; Heberer M Int J Cancer; 1995 Oct; 64(5):309-15. PubMed ID: 7591302 [TBL] [Abstract][Full Text] [Related]
18. In vitro priming with adenovirus/gp100 antigen-transduced dendritic cells reveals the epitope specificity of HLA-A*0201-restricted CD8+ T cells in patients with melanoma. Linette GP; Shankara S; Longerich S; Yang S; Doll R; Nicolette C; Preffer FI; Roberts BL; Haluska FG J Immunol; 2000 Mar; 164(6):3402-12. PubMed ID: 10706736 [TBL] [Abstract][Full Text] [Related]
19. Immunization of stage IV melanoma patients with Melan-A/MART-1 and gp100 peptides plus IFN-alpha results in the activation of specific CD8(+) T cells and monocyte/dendritic cell precursors. Di Pucchio T; Pilla L; Capone I; Ferrantini M; Montefiore E; Urbani F; Patuzzo R; Pennacchioli E; Santinami M; Cova A; Sovena G; Arienti F; Lombardo C; Lombardi A; Caporaso P; D'Atri S; Marchetti P; Bonmassar E; Parmiani G; Belardelli F; Rivoltini L Cancer Res; 2006 May; 66(9):4943-51. PubMed ID: 16651452 [TBL] [Abstract][Full Text] [Related]
20. Improved detection of melanoma antigen-specific T cells expressing low or high levels of CD8 by HLA-A2 tetramers presenting a Melan-A/Mart-1 peptide analogue. Maeurer MJ; Necker A; Salter RD; Castelli C; Höhn H; Karbach J; Freitag K; Neukirch C; Knuth A; Jäger E Int J Cancer; 2002 Jan; 97(1):64-71. PubMed ID: 11774245 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]